Navigation Links
Pharmos Corporation Reports 2011 Second Quarter Results
Date:8/8/2011

s related to conducting a non-human primate toxicology study needed for this trial. These increases were slightly offset by a reduction of various facility related expenses as the Company continued to reduce overall facility costs.

General and administrative expenses for the second quarter of 2011 decreased by $41,077, or 14%, from $300,492 in 2010 to $259,415 in 2011. The primary reductions were a $30,000 reduction in consultant and professional fees and an $11,000 reduction in salaries and benefits. Professional fees have decreased as there were business development fees in 2010 related to a possible reverse merger candidate which eventually was not pursued. The decrease in payroll costs in 2011 reflects lower stock compensation costs and the elimination of an administrative position in 2010.  

At June 30, 2011, the Company had approximately $2.1 million in cash and cash equivalents which is expected to be sufficient to fund current operations through at least March 31, 2012.  

Six-months Ended June 30, 2011For the six months ended June 30, 2011, Pharmos recorded a net loss of $1.1 million, or $0.02 per share compared to a net loss of $0.9 million, or $0.02 per share for the six months ended June 30, 2010.  

Research & development expenses for the first half of 2011 increased by $269,896 or 119% from $226,358 in 2010 to $496,254 in 2011. The primary areas include a $142,000 increase in clinical study fees and a $167,000 increase in consultant and professional fees which were offset by a $39,000 reduction in various other areas. Consulting and professional fees increased substantially as the Company conducted work in preparation for initiating a proof-of-concept trial in gout patients using Levotofisopam. Clinical study fees increased due to costs related to manufacturing capsules needed for this trial and costs related to conducting a non-human primate toxicology study. These increases were slightly offset by a red
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. Pharmos Issues Business Update on Dextofisopam Trial and Financing
3. Pharmos Corporation Reports 2009 Third Quarter Results
4. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
5. Pharmos Corporation Reports 2010 Third Quarter Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... MELVILLE, N.Y. , Nov. 21, 2014 /PRNewswire/ ... of the world,s largest health care services companies, and ... world,s largest provider of health care products and services ... announced that the companies have entered into a long-term ... service and product offerings to office-based medical practices.  This ...
(Date:11/21/2014)... research firm Kalorama information says that 2014 will be ... medical device industry.  The firm thinks the $360 billion-dollar ... growth this year, which led firms to look to ... entrance by acquisition into new competitive zones.  The company ... Global Market for Medical Devices, 5 th Edition ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... The Intellectual Property portfolio of TIGR® Matrix ... the granting of a second U.S. patent related to ... was developed based on the hypothesis that soft tissue ... mechanical load – a process known as ,mechanotransduction, which ...
... PRGO;TASE) today announced that it has received final approval ... abbreviated new drug application (ANDA) for Desloratadine tablets (5 ... upon its filing of an ANDA containing a Paragraph ... the terms of the settlement, Perrigo can commercially launch ...
Cached Medicine Technology:Novus Scientific Announces a New U.S. Patent for a Mesh Implant Comprising Two Different Resorbable Materials with Different Degradation Times and Specific Mechanical Behaviours; U.S. Patent No. -- 8,083,755 2Perrigo Announces FDA Final Approval for Desloratadine 2
(Date:11/21/2014)... (HealthDay News) -- The cost of diabetes care in ... years, climbing to more than $322 billion annually, a ... were seen with prediabetes care, which have risen 74 ... the researchers added. In 2012, excess medical costs ... $1,000 for every American. That total includes $244 billion ...
(Date:11/21/2014)... Nov. 21, 2014 (HealthDay News) -- Scientists say they,ve mapped ... extracted from a British man,s brain, in hopes it might ... Nov. 21 in the journal Genome Biology , the ... man of Chinese ethnicity. "This infection is so rare ... was not diagnosed ... until the worm was pulled out ...
(Date:11/21/2014)... 21, 2014 MLF Biotech, Inc. has ... . Liv-Pro® Probiotics for Pets helps maintain digestive health ... a pet's intestinal flora after it experiences a period ... Liv-Pro Probiotics for Pets is a proprietary blend of ... seven live active bacteria strains that are safe and ...
(Date:11/21/2014)... November 21, 2014 Saint Luke’s ... With The Guidelines®–Heart Failure Gold-Plus Quality Achievement Award ... the American Heart Association/American College of Cardiology Foundation ... patients. , Get With The Guidelines–Heart Failure is ... provide the most up-to-date, research-based guidelines with the ...
(Date:11/21/2014)... Big Bud Farms announced today that ... Innovations with Ed Begley Jr., airing via Discovery Channel ... Big Bud Farms, growers of legal medical marijuana, provide ... of medical marijuana. , This segment of Innovations takes ... of products for medicating. Viewers will learn about the ...
Breaking Medicine News(10 mins):Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2
... found that the frequency with which critically-ill patients developed ... multidisciplinary medical center such as Mayo Clinic compared to ... National Healthcare Safety Network (NHSN). This is good news ... generally strong across the U.S. in intensive care units, ...
... children becoming unconscious after swallowing Aqua Dots beads led to ... the time, it was widely reported that the potentially toxic ... benign but more expensive 1,5-pentanediol (PD) in the manufacture of ... Suchard of the University of California, Irvine confirms these reports, ...
... Nancy Pelosi,issued the following statement today following reports on ... health has been met with great concern., "Senator ... Americans and a,great fighter for America,s children, workers and ... serve him well in this,challenge., "Our thoughts and ...
... spine conference and exhibition draws specialists from across the ... ... Medical Werks, a leading provider of,ceramic components for motion preserving, total disc ... be held in Geneva, Switzerland, May 26-31., The foremost scientific societies ...
... of,America, Inc. today announced that Lindsay Goldberg has ... will use the funds to close,several identified acquisitions ... http://www.newscom.com/cgi-bin/prnh/20071218/CLTU087LOGO ), Ambulatory Services of ... care services in partnership with physicians. In,December 2007, ...
... Foundation,today released the following statement by its founder and ... learned today that Senator Kennedy, a champion for healthcare ... himself facing this,disease. I have no doubt that Senator ... strength that have shaped his lifelong service to this,nation ...
Cached Medicine News:Health News:Intensive care units' prevention of pneumonia in critically-ill patients generally strong 2Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland 2Health News:Ambulatory Services of America, Inc. Announces Investment by Lindsay Goldberg 2
... surgery, the Alexis Wound Retractor provides ... from contamination. For open surgery, the ... minimizing the incision size. For laparoscopic ... in offering retraction and protection when ...
... Concept is a revolutionary motorized electronic ... in mind, Pipetman Concept features exclusive ... connectionthe only one of its kind ... Diamond Tips from Gilson, this product ...
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
... Wireless, internet-based alarm/monitoring ... compliance and security ... system. The Celaris ... incorporates communication technology, ...
Medicine Products: